8-K: Cyclo Therapeutics Secures $3 Million in Convertible Debt, Amends Prior Notes with Rafael Holdings

Cyclo Therapeutics has entered into a fourth amended agreement with Rafael Holdings, issuing a $3 million convertible note and amending previous notes to mature on December 21, 2024, with a potential merger on the horizon.

Summary

• Cyclo Therapeutics has secured a $3 million convertible promissory note from Rafael Holdings.
• This agreement is the fourth amendment to a series of note purchase agreements between the two companies.
• The new note matures on December 21, 2024, and carries a 5% annual interest rate.
• The note can be prepaid by Cyclo Therapeutics at any time.
• The principal amount of the note is convertible into Cyclo Therapeutics common stock at the option of Rafael Holdings.
• Conversion is automatic upon a Qualified Financing event and at Rafael's option upon a Sale Transaction.
• The company also amended prior notes to have the same maturity date of December 21, 2024.
• The prior notes will be discharged in full upon the closing of a merger with Rafael Holdings.
• Rafael Holdings currently holds approximately 31.4% of Cyclo Therapeutics' common stock.
• Cyclo Therapeutics intends to use the proceeds from the note for working capital and general corporate purposes.

Sentiment

Score: 5

Explanation: The document indicates a continued reliance on debt financing, which is not ideal, but the company has secured additional funds and has a potential merger on the horizon. The sentiment is neutral to slightly negative due to the ongoing need for financing and the potential for dilution.

Positives

• Cyclo Therapeutics has secured additional funding of $3 million through a convertible note.
• The amendment of prior notes provides clarity on the maturity date and potential discharge upon merger.
• The company has the option to prepay the note at any time.
• The funds will be used for working capital and general corporate purposes, which can support operations.

Negatives

• The company is relying on convertible debt financing, which could lead to dilution if converted.
• The interest rate on the note increases to 12% upon an event of default.
• The company has a history of amending note purchase agreements with Rafael Holdings, indicating a potential need for ongoing financing.
• The company is dependent on Rafael Holdings for financing, which could limit its options.

Risks

• The company's reliance on convertible debt could lead to significant dilution of existing shareholders if the notes are converted to equity.
• Failure to meet payment obligations could trigger an event of default, increasing the interest rate to 12%.
• The merger with Rafael Holdings is subject to conditions and approvals, and may not be completed.
• The company's financial health is dependent on securing additional funding and completing the merger.

Future Outlook

The company intends to use the proceeds of the note for working capital and general corporate purposes, and the merger with Rafael Holdings is pending.

Management Comments

• The company intends to use the proceeds of the Note for working capital and general corporate purposes.

Industry Context

The biotech industry often relies on debt financing, especially for companies in the development stage. This agreement is a continuation of a series of financing rounds for Cyclo Therapeutics, indicating a need for ongoing capital.

Comparison to Industry Standards

• Convertible debt financing is a common practice in the biotech industry, especially for companies that are pre-revenue or in the early stages of commercialization.
• The 5% interest rate on the note is relatively standard for this type of financing, but the increase to 12% upon default is a significant risk.
• The conversion terms are also typical, with the conversion price often tied to a future financing round or a sale transaction.
• Companies like Cassava Sciences and Amylyx Pharmaceuticals have also used convertible debt to fund their operations and research.
• The repeated amendments to the note purchase agreements and the pending merger with Rafael Holdings suggest that Cyclo Therapeutics is in a period of significant financial and strategic transition.

Related Party Transactions

• The transaction is with Rafael Holdings, a significant shareholder of Cyclo Therapeutics, making it a related party transaction.

Stakeholder Impact

• Shareholders may experience dilution if the convertible notes are converted into common stock.
• Employees may benefit from the additional funding, which could support job security and company operations.
• Creditors may be impacted by the company's debt obligations and potential merger.
• Customers and suppliers may see continued operations and stability due to the additional funding.

Next Steps

• Cyclo Therapeutics will use the funds for working capital and general corporate purposes.
• The company will continue to work towards the completion of the merger with Rafael Holdings.
• The company will need to manage its debt obligations and potential dilution from the convertible notes.

Key Dates

Keywords

convertible note, promissory note, Rafael Holdings, merger, financing, debt, working capital, common stock, maturity date, convertible securities